Category Archives: Cell Medicine

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/lffnp7/stem_cell_research) has announced the addition of the "Stem Cell Research Products: Opportunities, Tools & Technologies 2012 (Updated)" report to their offering. Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into any mature cell type. Several broad categories of stem cells exist, including embryonic stem cells, derived from blastocysts; fetal stem cells, obtained from aborted fetuses; adult stem cells, found in adult tissues; cord blood stem cells, isolated from umbilical tissue; dental stem cells, derived from deciduous teeth; cancer stem cells, which give rise to clonal populations of cells that form tumors or disperse in the body; and animal stem cells, derived from non-human sources. In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult organisms, stem and progenitor cells act as a repair system for the body, replenishing specialized cells. Of interest to researchers is the potential for use of stem cells in regenerative medicine to treat conditions ranging from diabetes, to cardiovascular disease and neurological disorders. Additionally, the ability to use stem cells to improve drug target validation and toxicology screening is of intense interest … Continue reading →

DANVERS, Mass.--(BUSINESS WIRE)-- Cell Signaling Technology, Inc. (CST) of Danvers, MA is pleased to announce the development of a new discovery platform for antigen-specific monoclonal antibodies. This novel antibody discovery technology, named NG-XMTTM, harnesses the power of proteomics to identify and clone antigen-specific monoclonal antibodies directly from the circulating serum of an immunized animal. As described in the May print issue of Nature Biotechnology [30, 447 452 (2012)], NG-XMTTM technology enables the isolation of monoclonal antibodies with antigen-specific activities that recapitulate or surpass those of the original affinity-purified polyclonal antibodies found in the sera of immunized rabbits and mice. Our NG-XMTTM proteomics-based technology is faster and more efficient than traditional hybridoma-based methods, said Roberto D. Polakiewicz, Ph.D., CST Chief Scientific Officer. Moreover, our proprietary and patent pending technology can be applied to the development of therapeutically relevant human monoclonal antibodies for vaccine development and for understanding basic questions in immunology. CST has long been an industry leader in the development and manufacture of high performance antibodies for basic and clinical research, and we are excited to announce this breakthrough in monoclonal antibody technology. NG-XMT technology is ready for commercialization, said Fenel M. Eloi, CST Chief Operating Officer. CST is exploring … Continue reading →

ScienceDaily (May 10, 2012) This summer's action film, "The Amazing Spider-Man," is another match-up between the superhero and his nemesis the Lizard. Moviegoers and comic book fans alike will recall that the villain, AKA Dr. Curt Connors, was a surgeon who, after losing an arm, experimented with cell generation and reptilian DNA and was eventually able to grow back his missing limb. The latest issue of the journal Physiology contains a review article that looks at possible routes that unlock cellular regeneration in general, and the principles by which hair and feathers regenerate themselves in particular. The authors apply what is currently known about regenerative biology to the emerging field of regenerative medicine, which is being transformed from fantasy to reality. Review Article While the concept of regenerative medicine is relatively new, animals are well known to remake their hair and feathers regularly by normal regenerative physiological processes. In their review, the authors focus on (1) how extrafollicular environments can regulate hair and feather stem cell activities and (2) how different configurations of stem cells can shape organ forms in different body regions to fulfill changing physiological needs. The review outlines previous research on the role of normal regeneration of … Continue reading →

Connie K. Ho for RedOrbit.com A new study by researchers at the University of California, Los Angeles (UCLA) has discovered two adult stem cell-like subpopulations in adult human skin. The findings allow for further research to be done in the area of personalized medicine and patient-specific cellular therapies. The study, using technology from Fibrocell Science, allowed the researchers to identify and confirm two types of cells in human skin cell cultures; the possible source of stem cell-like subpopulations from skin biopsies would be faster to perform, painless, and less invasive than current extractions from adipose tissues and bone marrow. The research, featured in the inaugural issue of BioResearch Open Access, discusses two subtypes of cells. BioResearch Open Access is a bimonthly, peer-reviewed journal. It features scientific topics like biochemistry, bioengineering, gene therapy, genetics, microbiology, neuroscience, regenerative medicine, stem cells, systems biology, tissue engineering and biomaterials, and virology. Being able to identify two sub-populations of rare, viable and functional cells that behave like stem cells from within the skin is an important finding because both cell types have the potential to be investigated for diverse clinical applications, commented Dr. James A. Bryne, lead author of the report. Brynes research, first at … Continue reading →

SEATTLE, May 10, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (CTIC) today announced that it has received conditional marketing authorization from the European Commission ("EC") for Pixuvri (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas ("NHL"). Pixuvri is the first approved treatment in the European Union ("EU") in this patient setting. (Photo: http://photos.prnewswire.com/prnh/20120510/SF05192) The decision allows CTI to market Pixuvri in the 27 Member States of the EU as well as in Iceland, Liechtenstein and Norway. CTI expects to make Pixuvri immediately available in the EU, initially through a named patient program. CTI plans to market and commercialize Pixuvri with its own sales force in the EU starting in the 2nd half of 2012. "Pixuvri is a welcome addition in our efforts to control disease progression in these late-stage aggressive NHL patients as it has demonstrated a significant benefit compared to standard treatments used at this stage of disease. By addressing this unmet need, Pixuvri adds an important treatment option for patients," said Norbert Schmitz, M.D., Ph.D., Head of the Department of Hematology, Askelepios Klinik St. Georg in Hamburg, Germany. "The EC's decision for Pixuvri is an important milestone for adult … Continue reading →

SEATTLE, May 10, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (CTIC) today announced that it has received conditional marketing authorization from the European Commission ("EC") for Pixuvri (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas ("NHL"). Pixuvri is the first approved treatment in the European Union ("EU") in this patient setting. (Photo: http://photos.prnewswire.com/prnh/20120510/SF05192) The decision allows CTI to market Pixuvri in the 27 Member States of the EU as well as in Iceland, Liechtenstein and Norway. CTI expects to make Pixuvri immediately available in the EU, initially through a named patient program. CTI plans to market and commercialize Pixuvri with its own sales force in the EU starting in the 2nd half of 2012. "Pixuvri is a welcome addition in our efforts to control disease progression in these late-stage aggressive NHL patients as it has demonstrated a significant benefit compared to standard treatments used at this stage of disease. By addressing this unmet need, Pixuvri adds an important treatment option for patients," said Norbert Schmitz, M.D., Ph.D., Head of the Department of Hematology, Askelepios Klinik St. Georg in Hamburg, Germany. "The EC's decision for Pixuvri is an important milestone for adult … Continue reading →

BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Srl, a subsidiary of Celgene Corporation (NASDAQ: CELG - News), today announced that results from three phase III studies evaluating the use of continuous REVLIMID (lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine. All three publications highlight the expanding body of clinical evidence supporting lenalidomide treatment in these areas. Continuous Lenalidomide Therapy (non-transplant eligible population): The first article highlights a Celgene-sponsored study of continuous lenalidomide treatment in elderly patients newly diagnosed with multiple myeloma. Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma (MM-015) This double-blind, phase III, multicenter, randomized study conducted by Celgene compared melphalanprednisonelenalidomide induction followed by lenalidomide maintenance (MPR-R), with melphalanprednisonelenalidomide (MPR), or melphalanprednisone (MP) followed by placebo in 459 patients aged 65 years with newly-diagnosed myeloma who were not eligible for autologous stem-cell transplant. http://www.nejm.org/doi/full/10.1056/NEJMoa1112704 Post-transplant maintenance The two additional articles published in the edition highlighted cooperative group studies that evaluated the use of lenalidomide maintenance following autologous stem cell transplant (ASCT). In each of the studies, one funded by the National Cancer Institute and … Continue reading →

FARMINGTON, Conn., May 8, 2012 /PRNewswire-iReach/ -- Global Information Inc. is pleased to announce two significant new reports Opportunities in Human Embryonic Stem Cell (hESC) ProductsHuman embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, the stage reached 4 to 5 days after fertilization. They are the most pluripotent of all stem cell types, able to develop into any of over 200 different cell types in the human body, rending them tremendously useful for their therapeutic potential. However, human embryonic stem cell research is heavily encumbered by patents held by the University of Wisconsin's Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for guidance for companies seeking to develop new products. BioInformant's new Opportunities in Human Embryonic Stem Cell (hESC) Products market research report explores the complex IP landscape affecting development of human embryonic stem cell products, providing clear guidance for companies entering or already within the market. Over the past 15 years, WARF has been the major "gatekeeper" in determining which research product companies are able to conduct research, create commercial products, and develop novel therapies using hESCs. To date, WARF has entered into licensing agreements with only 27 commercial partners … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Dublin - Research and Markets (http://www.researchandmarkets.com/research/t99fl5/biomedical_science) has announced the addition of John Wiley and Sons Ltd's new book "Biomedical Sciences: Essential Laboratory Medicine" to their offering. Biomedical Sciences is an indispensable, all encompassing core textbook for first/ second year biomedical science students that will support them throughout their undergraduate career. The book includes the key components of the IBMS accredited degree programmes, plus sections on actual practice in UK hospital laboratories (including the compilation of a reflective portfolio). The book is visually exciting, and written in an interesting and accessible manner while maintaining scientific rigour. Highlighted boxes within the text link the theory to actual clinical laboratory practice for example, the histopathology chapter includes a photographically illustrated flow chart of the progress of a specimen through the histopathology lab, so that students can actually see how the specimen reception/inking/cut-up/cassette/block/section/stain system works, with an emphasis on the safety procedures that ensure specimens are not confused). Key Topics Covered: Chapter 1 Anatomy and physiology of major organ systems Chapter 2 Pathophysiology Chapter 3 Clinical cell biology and genetics Chapter 4 Cellular pathology Chapter 5 Clinical chemistry Read more: Research and Markets: Biomedical Sciences: Essential Laboratory Medicine … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/4zkdn4/skeletal_biology_a) has announced the addition of John Wiley and Sons Ltd's new book "Skeletal Biology and Medicine I: Mechanisms Regulating Bone Mass" to their offering. The volume features current basic, clinical, and translational research on aspects of skeletal morphogenesis and remodeling in health and disease. Papers survey vital new insights into the mechanisms of bone development and restructuring, including cellular and mechanical triggers, receptors and signaling pathways. Also covered are the effects of other physiological systems and disease states, such as immune system inflammation, diabetes, infection, and cancer on musculoskeletal health. Recent findings are shaping therapeutic directions that focus on both anti-resorptive and anabolic therapies. Basic scientists, clinical investigators, and clinicians with interests spanning endocrinology, physiology, cell biology, pathology, genetics, molecular biology, rheumatology, oncology, and other areas that relate to bone development and homeostasis will find this a valuable resource for the most recent developments in skeletal biology and medicine. This volume presents manuscripts stemming from the 4th New York Skeletal Biology and Medicine Conference, held at Mount Sinai School of Medicine in New York City on April 27-30, 2011. The papers included in this volume include two of the topic areas presented at the … Continue reading →